SEC Form 4 · accession 0001609284-26-000004

OnKure Therapeutics, Inc. · OKUR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Nicholas A Saccomano

Officer — President and CEO · Director

Period of report

Aug 7, 2026

Accepted (ET)

Aug 11, 2026 · 4:27 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001637715

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$4.14	Aug 7, 2026	A	150,000	A	—	Aug 6, 2036	Class A Common Stock	150,000	150,000	D
Employee Stock Option (right to buy)^F3,F4,F2	$21.20	Aug 7, 2026	D	2,359	D	—	Jan 10, 2032	Class A Common Stock	2,359	0	D
Employee Stock Option (right to buy)^F3,F4,F2	$4.14	Aug 7, 2026	A	2,359	A	—	Jan 3, 2032	Class A Common Stock	2,359	2,359	D
Employee Stock Option (right to buy)^F3,F4,F5	$13.99	Aug 7, 2026	D	1,485	D	—	Aug 29, 2033	Class A Common Stock	1,485	0	D
Employee Stock Option (right to buy)^F3,F4,F5	$4.14	Aug 7, 2026	A	1,485	A	—	Aug 29, 2033	Class A Common Stock	1,485	1,485	D
Employee Stock Option (right to buy)^F3,F4,F2	$13.99	Aug 7, 2026	D	8,449	D	—	Oct 14, 2033	Class A Common Stock	8,449	0	D
Employee Stock Option (right to buy)^F3,F4,F2	$4.14	Aug 7, 2026	A	8,449	A	—	Oct 14, 2033	Class A Common Stock	8,449	8,449	D
Employee Stock Option (right to buy)^F3,F4,F2	$13.99	Aug 7, 2026	D	16,898	D	—	Oct 14, 2033	Class A Common Stock	16,898	0	D
Employee Stock Option (right to buy)^F3,F4,F2	$4.14	Aug 7, 2026	A	16,898	A	—	Oct 14, 2033	Class A Common Stock	16,898	16,898	D
Employee Stock Option (right to buy)^F3,F4,F6	$18.20	Aug 7, 2026	D	542,232	D	—	Oct 3, 2034	Class A Common Stock	542,232	0	D
Employee Stock Option (right to buy)^F3,F4,F6	$4.14	Aug 7, 2026	A	542,232	A	—	Oct 3, 2034	Class A Common Stock	542,232	542,232	D

Explanation of responses

F11/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F3The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
F4Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
F51/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F61/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.